We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
-5.21%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$265M
AUM Growth
+$15.2M
Cap. Flow
+$21.8M
Cap. Flow %
8.22%
Top 10 Hldgs %
65.9%
Holding
29
New
8
Increased
10
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$16.3M
2
CELC icon
Celcuity
CELC
+$12.7M
3
IRON icon
Disc Medicine
IRON
+$8.44M
4
INZY
Inozyme Pharma
INZY
+$5.53M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.95M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$10.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.33M
3
ANAB icon
AnaptysBio
ANAB
+$7.83M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.2M
5
GERN icon
Geron
GERN
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$27.6M 10.43%
64,196
-1,401
-2% -$536K
IRON icon
2
Disc Medicine
IRON
$2.91B
$22.7M 8.57%
503,089
+248,286
+97% +$8.44M
CRNX icon
3
Crinetics Pharmaceuticals
CRNX
$8.88B
$21.5M 8.12%
479,681
-180,462
-27% -$8.33M
PCVX icon
4
Vaxcyte
PCVX
$8.12B
$16.3M 6.15%
215,680
+30,505
+16% +$2.08M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$15.4M 5.83%
113,224
+9,796
+9% +$1.33M
CYTK icon
6
Cytokinetics
CYTK
$10.9B
$14.7M 5.57%
272,036
+8,335
+3% +$503K
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$11.5B
$14.7M 5.56%
178,589
+59,401
+50% +$4.95M
COGT icon
8
Cogent Biosciences
COGT
$6.68B
$14.1M 5.33%
1,673,919
+78,898
+5% +$598K
CRGX
9
DELISTED
CARGO Therapeutics
CRGX
$14.1M 5.32%
+856,849
New +$16.3M
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$13.3M 5.02%
1,128,478
-313,474
-22% -$3.66M
CELC icon
11
Celcuity
CELC
$4.31B
$12.5M 4.71%
+760,941
New +$12.7M
MRUS
12
DELISTED
Merus
MRUS
$9.75M 3.68%
164,773
-211,856
-56% -$10.3M
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$2.02B
$8.62M 3.26%
419,654
+21,657
+5% +$453K
ABVX
14
Abivax
ABVX
$11.9B
$8.3M 3.14%
627,760
+4,790
+0.8% +$68.5K
IRWD icon
15
Ironwood Pharmaceuticals
IRWD
$635M
$7.26M 2.74%
1,113,824
+168,912
+18% +$1.19M
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
$7.08M 2.67%
713,536
-184,845
-21% -$1.9M
ANAB icon
17
AnaptysBio
ANAB
$1.72B
$6.26M 2.36%
249,609
-336,422
-57% -$7.83M
PHAT icon
18
Phathom Pharmaceuticals
PHAT
$873M
$6.11M 2.31%
593,306
+92,319
+18% +$951K
ITOS
19
DELISTED
iTeos Therapeutics
ITOS
$5.45M 2.06%
367,429
-19,666
-5% -$282K
INZY
20
DELISTED
Inozyme Pharma
INZY
$5.09M 1.92%
+1,140,310
New +$5.53M
NMRA icon
21
Neumora Therapeutics
NMRA
$298M
$3.83M 1.45%
+390,084
New +$4.04M
ELVN icon
22
Enliven Therapeutics
ELVN
$3.8B
$3.56M 1.34%
+152,178
New +$3.2M
LBPH
23
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.93M 0.73%
+71,442
New +$1.41M
RAPP
24
Rapport Therapeutics
RAPP
$2.04B
$1.63M 0.62%
+70,000
New +$1.62M
MORF
25
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.62M 0.61%
47,660
-37,972
-44% -$1.12M
1
2

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
FWM
FFT Wealth Management Philadelphia, Pennsylvania $552M AUM 16.82% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return

Saturn V Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Saturn V Capital Management held 29 positions worth $265M, up 6.1% from $249M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Saturn V Capital Management deployed $21.8M of net new capital in Q2 2024, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was CARGO Therapeutics: 856,849 shares worth $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $10.3M trimmed.

  • Saturn V Capital Management's largest Q2 2024 buy was CARGO Therapeutics: 856,849 shares worth $14.1M.
  • Saturn V Capital Management added most to Disc Medicine in Q2 2024, an estimated $8.44M increase.
  • Saturn V Capital Management's biggest Q2 2024 reduction was Merus, cutting an estimated $10.3M.
  • Saturn V Capital Management fully exited Apellis Pharmaceuticals in Q2 2024, selling an estimated $4.2M.
  • Saturn V Capital Management's ten largest holdings make up 66% of its $265M portfolio in Q2 2024.
  • Saturn V Capital Management opened 8 new positions and closed 3 in Q2 2024.
  • Saturn V Capital Management's portfolio value rose 6.1% quarter-over-quarter to $265M.

Based on Saturn V Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.